- Occupancy slipped 1.1 percentage points, reflecting what the company described as “challenging supply-and-demand dynamics” in several core markets.
- Rental income fell by $0.03 per share because of issues involving a single tenant in Seattle.
- Other income declined by $8.7 million, or roughly $0.05 per share, compared with the previous quarter.
Total revenue also retreated on a year-over-year basis. Alexandria generated $751.9 million in revenue during the third quarter, versus $791.6 million in the same period of 2024. Rental revenue accounted for $735.8 million, down from $775.7 million a year earlier.
Guidance trimmed amid industry headwinds
Management reduced its 2025 outlook for adjusted diluted FFO by $0.25 per share, setting a new midpoint of $9.01. The revision was attributed to lower-than-expected investment gains, weaker same-property performance, and the impact of the occupancy decline.
Citizens JMP noted that an increase in newly delivered laboratory space in markets such as Boston-Cambridge, the San Francisco Bay Area, and San Diego has coincided with a slowdown in venture funding for biotechnology startups. According to recent SEC filings, capital flows into the life science sector have moderated significantly compared with the pandemic-era peak, limiting expansion plans for many potential tenants.
The brokerage added that elevated construction costs and higher interest rates have made it more difficult for developers to commence new projects or refinance existing ones, thereby pressuring valuations across the sector.
Market reaction and investment context
Following the downgrade, Alexandria shares were identified by Citizens JMP as among the worst performers to consider buying on a dip, implying that the stock’s risk-reward profile has become less attractive relative to select technology names. The firm pointed investors toward companies exposed to artificial intelligence and domestic manufacturing trends, which it views as offering superior near-term upside with lower downside risk.
The downgrade adds to a series of cautious outlooks from Wall Street covering real estate investment trusts (REITs) focused on specialized property types. Still, Alexandria retains investment-grade credit ratings and continues to develop projects in established clusters, including its flagship campuses in Kendall Square, Mission Bay, and South Lake Union.
Key metrics from Q3 2025
- Adjusted diluted FFO: $2.22 per share (Q2 2025: $2.33 per share)
- Total revenue: $751.9 million (Q3 2024: $791.6 million)
- Rental revenue: $735.8 million (Q3 2024: $775.7 million)
- Occupancy change: -1.1 percentage points sequentially
- Full-year 2025 adjusted FFO guidance: midpoint of $9.01 per share (previous midpoint: $9.26)
Outlook
Citizens JMP emphasized that the combination of softer demand, increased supply, and constrained funding could continue to weigh on Alexandria’s leasing velocity and rental growth in the coming quarters. While acknowledging the company’s leading franchise in the life science real estate niche, the brokerage reiterated that visibility on a recovery remains limited until capital markets conditions improve and excess laboratory space is absorbed.
Crédito da imagem: Insider Monkey
